SPECIAL REPORT
MOST SHARED
- Consumer Sentiment Falters, Despite Job Growth
- Bill Murray's View on the Economy
- Santelli's Morning Bond Report
- Videogame Sales Fell 34 Percent in January
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Home of the Oscars Battles For Kodak Sponsorship
- Greek Police Union Wants to Arrest EU, IMF Officials
- Stocks Stumble as Greek Talks Stall; Vix Soars
- How to Date a Wall Street Man
- Bonus Question Dogs Barclays’ CEO Bob Diamond
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Tesla Unveils First SUV: Model X
- New York Fashion Week Hits the Runway as Colors Pop
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Consumer Sentiment Falters, Despite Job Growth
- Obama to Exempt Religious Employers on Birth Control
- Bonus Bloodbath: Europe Banker Backlash Continues
- Diamond Investing: Why It's Not for the Faint of Heart
- SEC Reaches Settlement in Bear Stearns Fraud Case
- Israel Likely to Bomb Iran This Year: Political Analyst
- The World's Best Beers
- Rep. Bachus Faces Insider Trading Probe: Report
- In Europe, Stagnation as a Way of Life
RSS FEED
Pharma's Market
Text Size 
Roche Rocks Genentech
Genentech [DNA
Loading...
()
] shares dropped three percent today or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. Recently, there'd been reports that the Swiss drugmaker, which already has a majority stake in the California biotech, was going to raise the offer to around $94. So, it was surprising and, some might say, shocking when Roche announced this morning that it was willing to pay $86.50 a share instead of the original $89.
Late today, Genentech put out a press release urging shareholders to tell Roche to take a hike. Dr. Charles Sanders, the chairman of the special committee of the DNA Board of Directors that's been set up to deal with Roche, called Roche's move "unilateral and opportunistic...in an attempt to take advantage of current market conditions."
But in a research note to clients, Bill Tanner at Leerink Swann said investors should take the money. "We believe the shares are fundamentally overvalued." Leerink Swann may trade in DNA.
Other analysts and investors believe Genentech's stock could rally this spring when test results are expected on the cancer drug Avastin as an add-on treatment for colon cancer. If the data are good and the drug gets approved for that use, it could substantially increase Avastin sales. Genentech recently announced that the numbers could be available in April. I'm guessing they'll unveil the so-called topline data at that time and save the details to make a huge splash at this year's American Society of Clinical Oncology meeting.
Geoffrey Meacham at JPMorgan says if that Avastin study goes well that Genentech shares could be worth more than a hundred bucks. "We do not expect the majority of shareholders to participate in this tender offer, where most of the core holders have held the stock for several years and are believers in the adjuvant (add-on Avastin colon cancer treatment) opportunity and the long-term value of the company." JPM has done and wants to do more investment banking for DNA and it makes a market in DNA options, which were apparently active today.
And another Geoffrey...Geoffrey Porges at Sanford C. Bernstein writes, "This is clearly another high risk hardball negotiating strategy by Roche. We believe it has a significant risk of failing to impress sufficient Genentech independent shareholders to close the deal." A part of Bernstein owns at least one percent of DNA.
Now, I'm really looking forward to my live interview next Friday morning with the new Roche CEO Severin Schwan.
That'll be "First on CNBC" on "Squawk Box" at around 7:15 a.m. ET.
It's the first time he's talked to CNBC U.S. since he took over last year and launched the bid for DNA.
If you had the chance, what would you ask him?
Send me your questions or comments to
Data is a real-time snapshot *Data is delayed at least 15 minutes
